Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer (FAKTION)
A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor
Sponsor: AstraZeneca
A PHASE1/PHASE2 clinical study on Estrogen Receptor Positive Breast Cancer, this trial is ongoing. The trial is conducted by AstraZeneca and has accumulated 13 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Unknown → Active Not Recruiting
-
Sep 2024 — Dec 2025 [monthly]
Unknown PHASE1/PHASE2
Status: Active Not Recruiting → Unknown
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2018 — Nov 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2017 — Mar 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2017 — Nov 2017 [monthly]
Recruiting PHASE1_PHASE2
Status: Unknown Status → Recruiting
-
Jan 2017 — Sep 2017 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Cardiff and Vale University Health Board
- Cenduit LLC
- Covance
- Velindre NHS Trust
For direct contact, visit the study record on ClinicalTrials.gov .